Biosignal Ltd (ASX: BOS) has engaged US company Bioduro Inc to further develop two different classes of therapeutic compounds based on Biosignal’s novel technology. Biosignal’s therapeutic target markets are respiratory infections and urinary tract infections. BioDuro is a leading life science outsourcing services company with particular strengths in discovery and pre-clinical chemistry. [click link for full article]